Durveqtix

Durveqtix is a medicine used to treat adults with severe or moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults who have not developed inhibitors (proteins made by the body’s natural defenses) against factor IX and who do not have antibodies against the virus contained in the medicine (see section on how the medicine works). Durveqtix contains the active substance fidanacogene elaparvovec and is a type of advanced therapy medicine called a ‘gene therapy product’. This is a type of medicine that works by delivering genes into the body.